Bio

Master degree in biochemistry and molecular biology, bachelor degree in pharmaceutical chemistry. Over 20 years of professional career in pharmaceutical industry with deep rooted industrial knowledge and resources in China, seasoned experience in licensing, JV, M&A and investments with 20+ successful deals. Joined Hermed Capital in 2015, Mr. Wu responsible for pharma and biotech investment, successfully completed 4 deals (Diamedica, Henlius, AADi and Hinvoa Pharma) and provided essential value-added support; Diamedica (DMAC, NASD) & Henlius (02696, HK) were listed by IPO; Hinova Pharma is in IPO process; AADi’s embedded value has grown significantly after submission of its first product to FDA. Prior to joining Hermed Capital, Mr. Wu was the BD head of Kanghong Pharmaceutical (002773, SH); BD head and R&D director of Sichuan Hebang Group.